Assignee
IMCLONE LLC
US·12 granted patents·11 pending applications·175 citations·filing 2004–2020
Top patents by PatentIndex Score
23 records- 0196US7598350B2Human anti-epidermal growth factor receptor antibodyIMCLONE LLC·Filed 2005·Granted Oct 6, 2009·73 cites·4 claims
- 0294US7740850B2PDGFRβ-specific antibodiesIMCLONE LLC·Filed 2008·Granted Jun 22, 2010·31 cites·6 claims
- 0392US8043618B2Fibroblast growth factor receptor-3 (FGFR-3) inhibitors and methods of treatmentIMCLONE LLC·Filed 2009·Granted Oct 25, 2011·14 cites·6 claims
- 0492US7972596B2Antibodies against vascular endothelial growth factor receptor-1IMCLONE LLC·Filed 2005·Granted Jul 5, 2011·23 cites·6 claims
- 0582US7947811B2Antibodies that bind specifically to human RON proteinIMCLONE LLC·Filed 2008·Granted May 24, 2011·14 cites·7 claims
- 0678US7638605B2Fully human antibodies directed against the human insulin-like growth factor-1 receptorIMCLONE LLC·Filed 2004·Granted Dec 29, 2009·13 cites·28 claims
- 0776US7968093B2Fully human antibodies directed against the human insulin-like growth factor-1 receptorIMCLONE LLC·Filed 2009·Granted Jun 28, 2011·3 cites·14 claims
- 0868US7951370B2Anti-TYRP1 antibodiesIMCLONE LLC·Filed 2009·Granted May 31, 2011·2 cites·8 claims
- 0967US9375488B2Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatmentIMCLONE LLC·Filed 2014·Granted Jun 28, 2016·2 cites·18 claims
- 1059US2011091470A1Anti-flt3 antibodiesIMCLONE LLC·Filed 2009·Application pending·0 cites
- 1148US2020071415A1Combination therapy for pancreatic cancerIMCLONE LLC·Filed 2018·Application pending·0 cites
- 1247US7972600B2IGF-IR antagonists as adjuvants for treatment of prostate cancerIMCLONE LLC·Filed 2007·Granted Jul 5, 2011·0 cites·13 claims
- 1346US2010221267A1Pdgfr beta-specific inhibitorsIMCLONE LLC·Filed 2010·Application pending·0 cites
- 1444US8784818B2Anti-VEGFR-3 antibody compositionsIMCLONE LLC·Filed 2013·Granted Jul 22, 2014·0 cites·6 claims
- 1544US2019183972A1Combination of ramucirumab and pembrolizumab for the treatment of certain cancersIMCLONE LLC·Filed 2017·Application pending·0 cites
- 1643US2021113692A1Dosing regimenIMCLONE LLC·Filed 2020·Application pending·0 cites
- 1743US2019233523A1Combination therapy for cancerIMCLONE LLC·Filed 2017·Application pending·0 cites
- 1842US10766961B2Anti-VEGFR2 antibody therapy for hepatocellular carcinomaIMCLONE LLC·Filed 2015·Granted Sep 8, 2020·0 cites·20 claims
- 1941US2020062850A1Combination of an anti-vegfr-2 antibody and an anti-pd-l1 antibody for the treatment of cancerIMCLONE LLC·Filed 2017·Application pending·0 cites
- 2040US2018207268A1Combination therapy for cancerIMCLONE LLC·Filed 2016·Application pending·0 cites
- 2138US2017333554A1Dosing regimenIMCLONE LLC·Filed 2017·Application pending·0 cites
- 2235US2017137523A1Therapy for gistIMCLONE LLC·Filed 2015·Application pending·0 cites
- 2331US2017129958A1Combination therapyIMCLONE LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when IMCLONE LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →